{"id":"W3081830235","doi":"10.1056/nejmoa2022190","title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5037,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada); University of Toronto; McGill University Health Centre; St. Michael's Hospital","funders":"Eli Lilly and Company; Boehringer Ingelheim","keywords":"Empagliflozin; Heart failure; Medicine; Ejection fraction; Cardiology; Diabetes mellitus; Internal medicine; Benzhydryl compounds; Broad spectrum; Heart failure with preserved ejection fraction; Type 2 diabetes; Endocrinology; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}